Inve India ▾
ININDGN

Indegene Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 30 Apr 2026

Indegene reported a milestone Q4 and full year FY26, with revenues exceeding ₹1,000 crores and ₹3,500 crores respectively for the first time, driven by strong customer growth and strategic GenAI-led innovation. Adjusted EBITDA showed robust growth, and cash generation was strong. However, reported PAT was impacted by one-time charges related to currency volatility and a legal settlement, though adjusted PAT showed positive growth. The company expressed confidence in FY27 growth, driven by scaling current initiatives and strategic acquisitions.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q4 FY26: revenue up 37.8%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue282 287 267 256 307 +9%290 +1%368 +38%
EBITDA46 52 40 37 71 +54%38 −27%103 +158%
Net profit45 50 54 45 60 +33%35 −30%72 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.